All In MedTech

Company

Accuray

Funding, FDA decisions, device trials, adverse event reports and recalls filed under this company's name in public data. Records are matched by name, so a subsidiary or an unusual spelling can be missed.

Last checked: Nov 20, 2026Source: SEC EDGAR, openFDA and ClinicalTrials.govMethods & limitations

This company is not on our public-company list, so only this exact name is matched. Naming a company here is not a recommendation of it or of any security.

Financing

Public company. Figures from its SEC financial statements.

Public

Listed

ARAY

Nasdaq · ACCURAY INC

Public float

$86.9M

Value of shares held by non-insiders on Dec 31, 2025

Revenue

$402M

Fiscal year ending Jun 30, 2026

Net income

-$49.2M

Fiscal year ending Jun 30, 2026

R&D spending

$37.8M

Fiscal year ending Jun 30, 2026

Cash

$42.3M

As of Sep 30, 2026

Long-term debt

$95.0M

As of Sep 30, 2026

Shares outstanding

120.2M

As of Oct 31, 2026

Capital raised as a public company

Cash received from selling stock and borrowing, from each year's cash-flow statement in the annual report. Fiscal years, by the year each one ended.

YearIPOStock soldLong-term debtConvertible debt
2026–$665K––
2025–$1.6M––
2024–$2.2M––
2023–$2.2M––
2022–$3.9M––
2021–$3.0M––

Not in public filings: valuations, share prices and investors' names. Private databases such as PitchBook and Crunchbase estimate these from press releases and surveys. Not every round is filed: companies raising under other exemptions, or from foreign investors only, may not file Form D. Nothing here is investment advice.

Investors

5%+ shareholders from SEC Schedule 13D/13G filings since Dec 1, 2024, and SBIR/STTR grants (NIH through Nov 10, 2026, other agencies through 2023). Venture investors in private rounds are not in public filings.

The investor database is part of the paid tier

For Accuray we have 1 shareholder with 5% or more.

It is included for signed-in readers who have credit, along with the daily news digest. Credit is also what pays for AI device summaries.

Latest FDA decisions

The 8 newest of 13 since 2015.

Search the Clearance Tracker

10 more FDA decisions with a free account

Device trials

Trials on ClinicalTrials.gov that list this company as lead sponsor, most recently updated first.

Open in the Trial Radar

No device trials list this company as lead sponsor.

Reports received

6

Received Nov 1, 2025 to Nov 20, 2026

Malfunction reports

4

67% of reports

Injury reports

1

17% of reports

Death reports

1

17% of reports

Adverse event reports received per month

Reports that name this company as manufacturer, by the date FDA received them. The newest month is incomplete.

Search the MAUDE Monitor
  • Malfunction
  • Injury
  • Death
  • Other
View as table
MonthMalfunctionInjuryDeathOther
Dec 230200
Jan 241000
Feb 240100
Mar 240100
Apr 240000
May 241000
Jun 241000
Jul 241000
Aug 240000
Sep 240000
Oct 242000
Nov 240000
Dec 240000
Jan 250000
Feb 250000
Mar 250000
Apr 250000
May 250000
Jun 250000
Jul 250100
Aug 251100
Sep 250000
Oct 250000
Nov 252000
Dec 251000
Jan 260000
Feb 260000
Mar 260000
Apr 260000
May 260000
Jun 260100
Jul 260000
Aug 261000
Sep 260000
Oct 260010
Nov 260000

Device types named most often

Last 12 months, by FDA product code. A company that sells more gets more reports.

Brand names named most often

Last 12 months, as written on the reports. One product can appear under several spellings.

1 more in this ranking with a free account

Recent recalls

From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.

38 more recall records with a free account

Back to all tools

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.